Osier FH

Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions.Payne RO, Silk SE, Elias SC, Miura K, Diouf A, Galaway F, de Graaf H, Brendish NJ, Poulton ID, Griffiths OJ, Edwards NJ, Jin J, Labbe GM, Alanine DG, Siani L, Di Marco S, Roberts R, Green N, Berrie E, Ishizuka AS, Nielsen CM, Bardelli M, Partey FD, Ofori MF, Barfod L, Wambua J, Murungi LM, Osier FH, Biswas S, McCarthy JS, Minassian AM, Ashfield R, Viebig NK, Nugent FL, Douglas AD, Vekemans J, Wright GJ, Faust SN, Hill AV, Long CA, Lawrie AM, Draper SJ
JCI Insight, (2017). 2:

Cord blood IgG and the risk of severe Plasmodium falciparum malaria in the first year of life.Murungi LM, Sonden K, Odera D, Oduor LB, Guleid F, Nkumama IN, Otiende M, Kangoye DT, Fegan G, Farnert A, Marsh K, Osier FH
Int J Parasitol, (2017). 47:153-162

Recent insights into humoral immunity targeting Plasmodium falciparum and Plasmodium vivax malaria.Boyle MJ, Reiling L, Osier FH, Fowkes FJ
Int J Parasitol, (2017). 47:99-104

Changes in Serological Immunology Measures in UK and Kenyan Adults Post-controlled Human Malaria Infection.Hodgson SH, Llewellyn D, Silk SE, Milne KH, Elias SC, Miura K, Kamuyu G, Juma EA, Magiri C, Muia A, Jin J, Spencer AJ, Longley RJ, Mercier T, Decosterd L, Long CA, Osier FH, Hoffman SL, Ogutu B, Hill AV, Marsh K, Draper SJ
Front Microbiol, (2016). 7:1604

Antibody acquisition models: A new tool for serological surveillance of malaria transmission intensity.Yman V, White MT, Rono J, Arca B, Osier FH, Troye-Blomberg M, Bostrom S, Ronca R, Rooth I, Farnert A
Sci Rep, (2016). 6:19472

Dynamics and role of antibodies to Plasmodium falciparum merozoite antigens in children living in two settings with differing malaria transmission intensity.Kangoye DT, Mensah VA, Murungi LM, Nkumama I, Nebie I, Marsh K, Cisse B, Bejon P, Osier FH, Sirima SB, MVVC Infant Immunology Study Group
Vaccine, (2016). 34:160-6

Standardization of the antibody-dependent respiratory burst assay with human neutrophils and Plasmodium falciparum malaria.Llewellyn D, Miura K, Fay MP, Williams AR, Murungi LM, Shi J, Hodgson SH, Douglas AD, Osier FH, Fairhurst RM, Diakite M, Pleass RJ, Long CA, Draper SJ
Sci Rep, (2015). 5:14081

Multiple clinical episodes of Plasmodium falciparum malaria in a low transmission intensity setting: exposure versus immunity.Rono J, Farnert A, Murungi L, Ojal J, Kamuyu G, Guleid F, Nyangweso G, Wambua J, Kitsao B, Olotu A, Marsh K, Osier FH
BMC Med, (2015). 13:114

Human antibodies fix complement to inhibit Plasmodium falciparum invasion of erythrocytes and are associated with protection against malaria.Boyle MJ, Reiling L, Feng G, Langer C, Osier FH, Aspeling-Jones H, Cheng YS, Stubbs J, Tetteh KK, Conway DJ, McCarthy JS, Muller I, Marsh K, Anders RF, Beeson JG
Immunity, (2015). 42:580-90

Evaluating controlled human malaria infection in Kenyan adults with varying degrees of prior exposure to Plasmodium falciparum using sporozoites administered by intramuscular injection.Hodgson SH, Juma E, Salim A, Magiri C, Kimani D, Njenga D, Muia A, Cole AO, Ogwang C, Awuondo K, Lowe B, Munene M, Billingsley PF, James ER, Gunasekera A, Sim BK, Njuguna P, Rampling TW, Richman A, Abebe Y, Kamuyu G, Muthui M, Elias SC, Molyneux S, Gerry S, Macharia A, Williams TN, Bull PC, Hill AV, Osier FH, Draper SJ, Bejon P, Hoffman SL, Ogutu B, Marsh K
Front Microbiol, (2014). 5:686

Limited antigenic diversity of Plasmodium falciparum apical membrane antigen 1 supports the development of effective multi-allele vaccines.Terheggen U, Drew DR, Hodder AN, Cross NJ, Mugyenyi CK, Barry AE, Anders RF, Dutta S, Osier FH, Elliott SR, Senn N, Stanisic DI, Marsh K, Siba PM, Mueller I, Richards JS, Beeson JG
BMC Med, (2014). 12:183

Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure.Biswas S, Choudhary P, Elias SC, Miura K, Milne KH, de Cassan SC, Collins KA, Halstead FD, Bliss CM, Ewer KJ, Osier FH, Hodgson SH, Duncan CJ, O'Hara GA, Long CA, Hill AV, Draper SJ
PLoS One, (2014). 9:e107903

New antigens for a multicomponent blood-stage malaria vaccine.Osier FH, Mackinnon MJ, Crosnier C, Fegan G, Kamuyu G, Wanaguru M, Ogada E, McDade B, Rayner JC, Wright GJ, Marsh K
Sci Transl Med, (2014). 6:247ra102

Opsonic phagocytosis of Plasmodium falciparum merozoites: mechanism in human immunity and a correlate of protection against malaria.Osier FH, Feng G, Boyle MJ, Langer C, Zhou J, Richards JS, McCallum FJ, Reiling L, Jaworowski A, Anders RF, Marsh K, Beeson JG
BMC Med, (2014). 12:108

Exposure to multiple parasites is associated with the prevalence of active convulsive epilepsy in sub-Saharan Africa.Kamuyu G, Bottomley C, Mageto J, Lowe B, Wilkins PP, Noh JC, Nutman TB, Ngugi AK, Odhiambo R, Wagner RG, Kakooza-Mwesige A, Owusu-Agyei S, Ae-Ngibise K, Masanja H, Osier FH, Odermatt P, Newton CR, Study of Epidemiology of Epilepsy in Demographic Sites group
PLoS Negl Trop Dis, (2014). 8:e2908

Correlates of protection for Plasmodium falciparum malaria vaccine development: current knowledge and future research.Beeson JG, Fowkes FJI, Reiling L, Osier FH, Drew DR, Brown GV
Malaria Vaccine Development: Over 40 Years of Trials and Tribulations, (2014). :80-104

A library of functional recombinant cell-surface and secreted P. falciparum merozoite proteins.Crosnier C, Wanaguru M, McDade B, Osier FH, Marsh K, Rayner JC, Wright GJ
Mol Cell Proteomics, (2013). 12:3976-86

Breadth of anti-merozoite antibody responses is associated with the genetic diversity of asymptomatic Plasmodium falciparum infections and protection against clinical malaria.Rono J, Osier FH, Olsson D, Montgomery S, Mhoja L, Rooth I, Marsh K, Farnert A
Clin Infect Dis, (2013). 57:1409-16

Analysis of antibodies to newly described Plasmodium falciparum merozoite antigens supports MSPDBL2 as a predicted target of naturally acquired immunity.Tetteh KK, Osier FH, Salanti A, Kamuyu G, Drought L, Failly M, Martin C, Marsh K, Conway DJ
Infect Immun, (2013). 81:3835-42

A threshold concentration of anti-merozoite antibodies is required for protection from clinical episodes of malaria.Murungi LM, Kamuyu G, Lowe B, Bejon P, Theisen M, Kinyanjui SM, Marsh K, Osier FH
Vaccine, (2013). 31:3936-42